Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Late-onset Neonatal Sepsis
Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Late-onset Neonatal Sepsis
The purpose of the study is to investigate the plasma levels of Soluble Urokinase Plasminogen
 Activator Receptor (suPAR) at the diagnosis and after treatment of sepsis, and to determine
 whether it has a diagnostic and prognostic value in late-onset neonatal sepsis.
Infection is a leading cause of neonatal morbidity and mortality worldwide. The clinical
 presentation of neonatal infection is subtle and nonspecific. Microbiologic cultures of
 clinical specimens, the gold standard for diagnosis, have low sensitivity and are not
 available in time to influence initial therapy. Therefore, reliable and rapid in vitro tests
 are needed for early diagnosis and management of infection in neonates. suPAR, secreted from
 the cells (neutrophils, lymphocytes, macrophages, endothelial cells) has recently been
 reported to be a potential biomarker for several infection diseases. The levels of suPAR have
 not been studied in newborn infants yet.
Inclusion Criteria:

 -  Infants with late-onset neonatal sepsis

 Exclusion Criteria:

 -  Infants without parents' consent